🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

203 results for “Novartis” Clear

  1. LTP001, Placebo to LTP001 1mg and 5mg hard gelatin capsules, LTP001

    Novartis Ophthalmics Europe

    Idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  2. Lutathera 370 MBq/mL solution for infusion, ATEZOLIZUMAB, Tevimbra 100 mg concentrate for solution for infusion, CARBOPLATIN, LysaKare 25 g/25 g solution for infusion, NETSPOT, ETOPOSIDE

    Novartis Ophthalmics Europe

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  3. Luxdegalutamide, DZR123, -, -, DOCETAXEL, CABAZITAXEL, ABIRATERONE, DZR123, ENZALUTAMIDE

    Novartis Ophthalmics Europe

    Metastatic castrate resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  4. Luxdegalutamide, GOZETOTIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Ophthalmics Europe

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  5. MAS825, -

    Novartis Ophthalmics Europe

    Still’s disease

    phase 2 small molecule active

    1 trial

  6. MBG453, VENETOCLAX, VENETOCLAX, AZACITIDINE, VENETOCLAX

    Novartis Ophthalmics Europe

    intermediate, high or very high risk MDS in adult patients chronic Myelomonocytic Leukemia - 2 (CMML-2) Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy

    phase 2 small molecule active

    1 trial

  7. MYCOPHENOLIC ACID , PREDNISONE, MYCOPHENOLATE SODIUM, PREDNISONE, MYCOPHENOLATE SODIUM, Placebo 0 mg hard gelatin capsule size 0 and size 2, (placebo to LNP023), METHYLPREDNISOLONE , IPTACOPAN, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, LNP023, Placebo to prednisone

    Novartis Ophthalmics Europe

    Lupus Nephritis Class III-IV, +/- V

    phase 2 small molecule active

    1 trial

  8. PARACETAMOL, Placebo to QUC398 150 mg/1 mL Solution for injection, QUC398, Paracetamol/Codeine phosphate hemihydrate Accord 500 mg/30 mg tablets

    Novartis Ophthalmics Europe

    Knee osteoarthritis

    phase 2 small molecule active

    1 trial

  9. PKN605, Placebo to PKN605 50 mg film-coated tablets

    Novartis Ophthalmics Europe

    Atrial Fibrillation

    phase 2 small molecule active

    1 trial

  10. PPY988A

    Novartis Ophthalmics Europe

    Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in participants already treated with GT005 in the previous studies GT005-01 (FOCUS), GT005-02 (EXPLORE) and GT005-03 (HORIZON).

    phase 2 small molecule active

    1 trial

  11. Paracetamol/Codeine phosphate hemihydrate Accord 500 mg/30 mg tablets, PARACETAMOL, DFV890, Placebo to DFV890 10mg, Placebo to DFV890 25mg, DFV890

    Novartis Ophthalmics Europe

    Knee Osteoarthritis

    phase 2 small molecule active

    1 trial

  12. Placebo to BYL719 50 mg film-coated tablets (Light Yellow) Placebo to BYL719 125 mg film-coated tablets (Dark Yellow), BYL719, BYL719, BYL719, BYL719, BYL719

    Novartis Ophthalmics Europe

    PIK3CA-Related Overgrowth Spectrum (PROS)

    phase 2 small molecule active

    1 trial

  13. Placebo to LTP001 00mg hard gelatin capsule, LTP001, LTP001, Placebo to LTP001 00mg hard gelatin capsule

    Novartis Ophthalmics Europe

    Part A: Healthy volunteers (Part A is not applicable to the EU; for information only) Part B: pulmonary arterial hypertension

    phase 2 small molecule active

    1 trial

  14. Placebo to MAS825 100 mg/1 mL Concentrate for solution for infusion / Solution for injection, -, CICLOSPORIN , MAS825

    Novartis Ophthalmics Europe

    Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis), X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency, or Cell division control protein 42 homolog (CDC42) mutation.

    phase 2 small molecule active

    1 trial

  15. Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device, TQJ230

    Novartis Ophthalmics Europe

    Calcific Aortic Valve Stenosis

    phase 2 small molecule active

    1 trial

  16. Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation

    Novartis Ophthalmics Europe

    Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with moderate and severe renal impairment and with normal renal function.

    phase 2 small molecule active

    1 trial

  17. RITUXIMAB, MYCOPHENOLATE MOFETIL, YTB323, FLUDARABINE PHOSPHATE, VOCLOSPORIN, TACROLIMUS, RITUXIMAB, MYCOPHENOLIC ACID, CYCLOPHOSPHAMIDE, TOCILIZUMAB, CYCLOPHOSPHAMIDE, AZATHIOPRINE, BELIMUMAB

    Novartis Ophthalmics Europe

    Active, refractory systemic lupus erythematosus (SLE), and active, refractory lupus nephritis (LN)

    phase 2 small molecule active

    1 trial

  18. SALBUTAMOL, FLUTICASONE PROPIONATE, NVA237, NVA237, SALMETEROL XINAFOATE, The Placebo is a generic Placebo, inhalation powder, hard capsule. It is used to match an active dosage forms (NVA237 12.5µg and NVA 237 25µg) in this clinical trial. The placebo comprises inactive excipients (magnesium stearate and lactose monohydrate) encapsulated in hard non-gelatin capsules matching those used for the active drug product.

    Novartis Ophthalmics Europe

    Asthma

    phase 2 small molecule active

    1 trial

  19. SODIUM CHLORIDE , DII235

    Novartis Ophthalmics Europe

    Cardiovascular risk reduction in participants with elevated Lp(a)

    phase 2 small molecule active

    1 trial

  20. Scemblix 20 mg film-coated tablets, Tasigna 200 mg hard capsules, Scemblix 40 mg film-coated tablets, Tasigna 150 mg hard capsules

    Novartis Ophthalmics Europe

    Chronic myeloid leukemia

    phase 2 small molecule active

    1 trial

  21. Scemblix 40 mg film-coated tablets

    Novartis Ophthalmics Europe

    CML-CP or CML-AP patients with T315I mutation

    phase 2 small molecule active

    1 trial

  22. Scemblix 40 mg film-coated tablets, Scemblix 40 mg film-coated tablets, Scemblix 20 mg film-coated tablets, Scemblix 40 mg film-coated tablets, NILOTINIB, NILOTINIB, Scemblix 20 mg film-coated tablets, IMATINIB, IMATINIB

    Novartis Ophthalmics Europe

    Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular response

    phase 2 small molecule active

    1 trial

  23. TIN816, Placebo to TIN816 70mg powder for solution for injection or infusion

    Novartis Ophthalmics Europe

    Acute kidney injury

    phase 2 small molecule active

    1 trial

  24. TIN816, Sterile 0.9% sodium chloride solution for infusion will be administered as placebo to participants randomized to the placebo treatment. The solution is ready to use in a 100mL infusion bag of 0.9% sodium chloride solution

    Novartis Ophthalmics Europe

    Sepsis associated acute kidney injury

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources